well
known
factor
viii
fviii
concentr
revolution
treatment
patient
haemophilia
consider
improv
patient
qualiti
life
transmiss
hepat
hav
hepat
b
hbv
hepat
hiv
signific
setback
mani
prevent
measur
implement
reduc
risk
viral
transmiss
transfus
plasma
product
includ
donor
screen
virucid
procedur
viru
erad
step
manufactur
exampl
bio
product
laboratori
bpl
introduc
fviiivon
willebrand
factor
vwf
concentr
manufactur
use
dri
h
known
broad
antivir
effect
last
year
well
toler
treatment
haemophilia
von
willebrand
diseas
vwd
without
transmiss
hepat
hepat
b
hepat
c
hiv
low
incid
inhibitor
new
product
bio
product
laboratori
elstre
uk
develop
includ
novel
chromatograph
purif
step
remov
unnecessari
protein
fibrinogen
fibronectin
addit
specif
step
includ
minim
transmiss
envelop
virus
includ
west
nile
dri
heat
h
process
use
known
inactiv
sar
viru
retain
two
specif
virucid
step
taken
manufactur
consid
effect
envelop
virus
eg
hav
parvoviru
normal
pharmacokinet
report
elsewher
patient
haemophilia
patient
vwd
nowaday
develop
inhibitor
antibodi
remain
concern
new
fviii
product
late
earli
two
outbreak
inhibitor
amongst
previous
treat
patient
ptp
treat
new
concentr
show
chang
manufactur
process
could
result
format
neoantigen
lead
inhibitor
format
sinc
essenti
evalu
new
fviii
concentr
ptp
establish
whether
unusu
antigen
paper
report
consolid
clinic
data
collect
prospect
period
year
two
studi
conduct
assess
safeti
efficaci
patient
sever
haemophilia
two
studi
call
pharmacokinet
pk
safeti
efficaci
se
conduct
design
virtual
ident
clinic
data
combin
report
major
differ
studi
one
pk
addit
provid
pharmacokinet
profil
patient
previou
fviii
pk
data
report
elsewher
studi
multicentr
intern
prospect
studi
compliant
guidelin
issu
committe
proprietari
medicin
product
cpmp
known
committe
medicin
product
human
use
chmp
ethic
committe
approv
written
inform
consent
obtain
clinic
assess
visit
schedul
ident
studi
prestudi
screen
week
prior
given
assess
follow
month
home
therapi
assess
end
period
follow
month
home
therapi
regular
phone
throughout
review
haemophilia
centr
patient
elig
inclus
male
year
old
haemophilia
basal
fviii
activ
time
diagnosi
without
inhibitor
least
exposur
day
ed
se
studi
exclus
criteria
histori
inhibitor
intern
normal
ratio
thrombocytopenia
platelet
clinic
signific
renal
diseas
creatinin
clinic
signific
liver
diseas
alanin
transaminas
level
three
time
upper
normal
limit
particip
anoth
clinic
trial
within
day
studi
entri
se
studi
patient
need
lymphocyt
count
patient
recruit
haemophilia
centr
poland
uk
use
prophylact
accord
prefer
specif
medic
prohibit
studi
except
fviii
product
safeti
assess
monitor
viral
marker
antiparvoviru
hiv
hbv
hcv
hav
specifi
time
fviii
inhibitor
screen
monthli
routin
biochemistri
haematolog
advers
event
ae
fviii
inhibitor
screen
perform
use
standard
activ
partial
thromboplastin
time
incub
techniqu
recommend
uk
haemophilia
centr
doctor
organ
ukhcdo
screen
test
posit
bethesdanijmegen
quantit
assay
perform
extent
exposur
also
determin
efficaci
assess
number
type
sever
bleed
new
bleed
bleed
ongo
bleed
bleed
requir
addit
dose
subject
assess
haemostasi
made
clinician
patient
sampl
size
chosen
studi
excess
prescrib
chmp
guidanc
descript
statist
present
subdivid
prophylact
use
modal
treatment
random
formal
compar
statist
test
use
prophylaxi
defin
least
two
prophylact
dose
per
week
total
patient
enrol
pk
studi
se
studi
except
one
patient
caucasian
patient
treat
prophylact
fig
patient
administ
intermitt
prophylact
dose
mostli
increas
physic
activ
consolid
baselin
demograph
particip
shown
tabl
durat
infus
patient
receiv
mean
period
week
tabl
signific
differ
mean
durat
treatment
per
patient
two
usag
group
week
prophylact
group
week
group
overal
experi
studi
altogeth
infus
use
studi
record
mean
ed
tabl
includ
patient
prophylaxi
dose
prophylact
infus
treat
bleed
use
infus
treat
bleed
dose
intermitt
prophylaxi
tabl
overal
mean
number
infus
administ
per
patient
polish
subject
fewer
ed
per
patient
uk
patient
tabl
dose
bleed
occur
patient
prophylaxi
mean
dosepati
use
new
bleed
iu
mean
total
ongo
bleed
iu
per
patient
comparison
patient
use
slightli
lower
dose
new
ongo
bleed
tabl
addit
patient
prophylact
group
patient
administ
intermitt
prophylact
dose
overal
mean
prophylact
dose
iu
per
patient
iu
prophylact
group
iu
intermitt
prophylaxi
group
tabl
patient
uk
use
higher
prophylact
dose
per
infus
poland
administ
frequent
prophylact
dose
prophylact
dose
per
week
per
patient
respect
tabl
treatment
spontan
bleed
studi
mean
number
bleed
per
patient
patient
use
prophylact
mean
new
bleed
per
week
per
patient
compar
patient
mean
new
bleed
per
week
per
patient
uk
patient
mean
bleed
rate
bleed
per
week
per
patient
wherea
polish
patient
bleed
per
week
per
patient
tabl
overal
bleed
joint
muscl
bleed
openoth
bleed
remain
locat
specifi
tabl
object
outcom
bleed
episod
assess
clinician
bleed
bleed
patient
patient
treat
prophylact
clinician
rate
therapi
excel
good
assess
bleed
episod
patient
report
clinic
respons
help
help
control
bleed
episod
assess
bleed
prophylact
group
group
tabl
consolid
ae
prophylact
group
one
patient
report
five
ae
group
patient
report
ae
event
overal
ae
occur
seven
patient
headach
frequent
ae
occur
three
patient
dizzi
report
two
patient
tabl
overal
one
ae
occur
everi
infus
safeti
variabl
patient
neg
screen
inhibitor
fviii
throughout
studi
viru
transmiss
occur
signific
chang
laboratori
valu
aim
studi
evalu
fviii
vwf
concentr
ptp
although
data
origin
formal
clinic
studi
outcom
repres
usual
clinic
practic
exampl
dose
given
nearest
whole
iu
vial
combin
safeti
efficaci
data
two
similar
studi
includ
report
studi
use
analys
prophylact
use
use
patient
random
comparison
appropri
howev
standard
manag
patient
sever
haemophilia
involv
either
one
treatment
modal
therefor
inclus
treatment
regimen
studi
allow
clinic
util
establish
comprehens
patient
use
prophylact
differ
age
use
although
minor
use
prophylact
overal
patient
tend
use
lower
dose
prophylact
group
treat
bleed
intermitt
prophylaxi
patient
use
prophylact
experienc
third
number
bleed
bleed
rate
bleed
per
week
per
patient
bleed
per
week
per
patient
respect
outcom
accord
two
treatment
modal
compar
expect
major
polish
patient
treat
consum
less
fviii
product
compar
treat
uk
efficaci
explor
qualit
assess
impact
prophylact
treatment
subject
outcom
spontan
bleed
assess
respons
yield
similar
posit
result
data
collect
spontan
bleed
provid
evid
efficaci
rel
fviii
product
compar
studi
result
studi
howev
indic
prophylact
use
effect
fewer
bleed
use
use
well
toler
patient
safeti
concern
use
either
prophylact
seven
patient
experienc
ae
time
number
ae
report
unusu
high
type
ae
compar
product
commonli
report
ae
headach
dizzi
ae
experienc
treatment
group
headach
format
inhibitor
current
repres
major
obstacl
success
treatment
patient
haemophilia
absenc
inhibitor
trial
support
use
clinic
practic
although
patient
ptp
vwf
content
may
contribut
outcom
find
confirm
clinic
safeti
efficaci
prophylact
manag
treatment
bleed
patient
sever
haemophilia
furthermor
concern
emerg
regard
fviii
inhibitor
articl
present
data
clinic
trial
fund
bio
product
laboratori
bpl
dr
clive
dash
work
consult
medic
director
bpl
rukhsana
contract
bpl
work
clinic
research
consult
dr
ernest
gascoign
employe
bpl
three
author
potenti
conflict
interest
involv
prepar
articl
